We release communications to in-network providers about changes to health plan procedures, policies and benefits, as well as information about larger initiatives. This page lists some of our issued notifications for reference.
Get familiar with a wide range of available programs and services for members and promote them to your patients, when appropriate.
Upcoming changes as we partner with Medica to align best practices and share technology.
For onboarding and ongoing reference, your all-in-one guide to resources and processes for all plan types under payer ID 39113.
Access information about our evolving partnership with Medica, an independent, nonprofit health plan headquartered in Minnetonka, Minnesota, and how we are using this partnership to strengthen our ability to provide high quality support for providers and members.
Upcoming changes & enhancements to the prior authorization experience with our health plan
Issued: August 14, 2024
Audience: All in-network providers
See August 14 provider communication (PDF)
Our planned mitigation to the security incident.
Issued: March 26, 2024
Audience: All in-network providers
See March 26 provider communication (PDF)
Updated FAQ for providers (PDF)
Services through Change Healthcare with any payer are not operating at this time.
Issued: March 8, 2024
Audience: All in-network providers
See March 8 provider communication (PDF)
2024 member plan and benefit highlights for provider awareness.
Issued: December 2023
Audience: All in-network providers
Effective date: 1/1/24
See 2024 changes (PDF)
2023 member plan and benefit highlights for provider awareness.
Issued: November 2022
Audience: All in-network providers
Effective date: 1/1/23
See 2023 changes (PDF)
Starting November 1, 2023, policy notices are published in our monthly newsletters.
Audience: all in-network providers
For pharmacy updates issued on and after April 1, 2022, see the medical and drug policy updates listed on this page.
Audience: All in-network providers
ALDURAZYME-laronidase, ARANESP-darbepoetin alpha, ELAPRASE-idursulfase, ELELYSO-taliglucerase alfa, Epoetin Alfa Products, NAGLAZYME-galsulfase, VIMIZIM-elosulfase, and retired policy (PDF)
Issued: February 2022
Effective date: 6/1/2022
Xeljanz (tofacitinib), Rinvoq (upadacitinib, Benlysta (belimumab, GAZYVA-obinutuzumab, SPINRAZA-nusinersen and retired policies (PDF)
Issued: February 2022
Effective date: 5/1/2022